CTSW represented Regor Pharmaceuticals in its sale of next-generation CDK inhibitors for breast cancer treatment to Genentech (a Roche Group member) for an upfront payment of $850 million plus milestone payments. CTSW advised on all aspects of the negotiation and transaction.
We are proud to support impactful transactions driving pharmaceutical innovation.